

Journal of the
American Academy of
DERMATOLOGY

December 1996

VOLUME 35 NUMBER 6

INDEX ISSUE



• CME article

Drug photosensitivity, idiopathic photodermatoses, and sunscreens

Ernesto González, MD, and Salvador González, MD

Boston, Massachusetts

HEALTH SCIENCES LIBRARY
University of Wisconsin

DEC 11 1996

1305 Linden Drive
Madison, WI 53706

M Mosby

ISSN 0190-9622

Editor

Richard L. Dobson, MD

Associate Editor

Bruce H. Thiers, MD

Editorial Office

Department of Dermatology
 Medical University of South Carolina
 171 Ashley Ave.
 Charleston, SC 29425-2215
 803-792-9155

Assistant Editors

Elizabeth A. Abel, MD

Mountain View, California

Jeffrey D. Bernhard, MD

Worcester, Massachusetts

Michael E. Bigby, MD

Boston, Massachusetts

Jeffrey P. Callen, MD

Louisville, Kentucky

Clay J. Cockerell, MD

Dallas, Texas

Mark V. Dahl, MD

Minneapolis, Minnesota

Madeleine Duvic, MD

Houston, Texas

Mary Maloney, MD

Hershey, Pennsylvania

Brian Nickoloff, MD

Ann Arbor, Michigan

Amy S. Paller, MD

Chicago, Illinois

Neal S. Penneys, MD

St. Louis, Missouri

Stuart J. Salasche, MD

Tucson, Arizona

Robert A. Schwartz, MD

Newark, New Jersey

Elizabeth Sherertz, MD

Winston-Salem, North Carolina

Alvin R. Solomon, MD

Atlanta, Georgia

Kenneth J. Tomecki, MD

Cleveland, Ohio

Founding Editor

J. Graham Smith, Jr., MD

Mobile, Alabama

Vol. 35, No. 6, December 1996, the Journal of the American Academy of Dermatology (ISSN 0190-9622) is published monthly (six issues per volume, two volumes per year) by Mosby-Year Book, Inc., 11830 Westline Industrial Dr., St. Louis, MO 63146-3318. Periodicals postage paid at St. Louis, Missouri, and additional mailing offices. Postmaster: Send address changes to Journal of the American Academy of Dermatology, Mosby-Year Book, Inc., 11830 Westline Industrial Dr., St. Louis, MO 63146-3318. Annual subscription rates: \$144.00 for individuals, \$248.00 for institutions. Printed in the U.S.A. Copyright © 1996 by the American Academy of Dermatology, Inc., P.O. Box 4014, Schaumburg, IL 60168-4014.

CONTENTS December 1996

CONTINUING MEDICAL EDUCATION

Drug photosensitivity, idiopathic photodermatoses, and sunscreens 871

Ernesto González, MD, and

Salvador González, MD

Boston, Massachusetts

CME examination 886

Answers to CME examination (Identification No. 896-111), November 1996 issue of the 888

Journal of the American Academy of Dermatology

CLINICAL AND LABORATORY STUDIES

Damage to hair follicles by normal-mode ruby laser pulses 889

Melanie C. Grossman, MD,

Christine Dierickx, MD,

William Farinelli, BS,

Thomas Flotte, MD,

and R. Rox Anderson, MD

Boston, Massachusetts

Psychologic effects of vitiligo: A critical incident analysis 895

Gerry Kent, PhD, and

Mohammed Al'Abadie, MD, PhD

Sheffield and Wolverhampton, United Kingdom

Chronic telogen effluvium: Increased scalp hair shedding in middle-aged women	899
David A. Whiting, MD, FRCP(Edinb) <i>Dallas, Texas</i>	
Increased proportion of aggressive-growth basal cell carcinoma in the Veterans Affairs population of Palo Alto, California	907
David A. Wrone, Susan M. Swetter, MD, Barbara M. Egbert, MD, Bruce R. Smoller, MD, and Paul A. Khavari, MD, PhD <i>Palo Alto and Stanford, California</i>	
Sunny Days, Healthy Ways: Evaluation of a skin cancer prevention curriculum for elementary school-aged children	911
David B. Buller, PhD, Mary K. Buller, MA, Barbara Beach, PhD, and Gregory Ertl, MD <i>Tucson and Yuma, Arizona</i>	
Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: Radiation port scleroderma	923
Daniel A. Davis, MD, Philip R. Cohen, MD, Marcia D. McNeese, MD, and Madeleine Duvic, MD <i>Galveston and Houston, Texas</i>	
Oral hairy leukoplakia in 71 HIV-seropositive patients: Clinical symptoms, relation to immunologic status, and prognostic significance	928
Ralf Husak, MD, Claus Garbe, MD, and Constantin E. Orfanos, MD <i>Berlin, Germany</i>	
THERAPY	
Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy	935
John A. Zic, MD, George P. Stricklin, MD, PhD, John P. Greer, MD, Marsha C. Kinney, MD, Yu Shyr, PhD, David C. Wilson, MD, and Lloyd E. King, Jr., MD, PhD <i>Nashville, Tennessee, and Lynchburg, Virginia</i>	
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution	946
Scott L. Gottlieb, MD, Jonathan T. Wolfe, MD, Floyd E. Fox, PhD, Barbara J. DeNardo, RN, William H. Macey, RN, Patricia G. Bromley, RN, Stuart R. Lessin, MD, and Alain H. Rook, MD <i>Philadelphia, Pennsylvania</i>	
Treatment of <i>Candida</i> nail infection with terbinafine	958
Rina Segal, MD, Aharon Kritzman, MD, Lia Cividalli, PhD, Zmira Samra, PhD, and Michael David, MD <i>Petah Tiqva, Israel</i>	

Continued on page 9A

DERMATOPATHOLOGY

- The starburst giant cell is useful for distinguishing lentigo maligna from photodamaged skin** 962
Lisa M. Cohen, MD *Boston, Massachusetts*

CLINICAL REVIEW

- Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses** 969
Stephanie Tseng, BA, Grace Pak, MD, Kenneth Washenik, MD, PhD,
Miriam Keltz Pomeranz, MD, and Jerome L. Shupack, MD
New York, New York

PEARLS OF WISDOM

- Surgical Pearl: The trephine punch for diagnosing panniculitis** 980
Julide Tok, MD, Irving Abrahams, MD, Margaret A. Ravits, MD, and
David N. Silvers, MD *New York, New York*
- Iotaderma # 35** 981
Jeffrey Bernhard, MD *Worcester, Massachusetts*

BRIEF COMMUNICATIONS

- Reactive perforating collagenosis in Treacher Collins syndrome** 982
Yong-Kwang Tay, MD, William L. Weston, MD, and John L. Aeling, MD
Denver, Colorado
- Septic microemboli in a Janeway lesion of bacterial endocarditis** 984
MAJ Richard P. Vinson, MC, USA, CPT Andrew Chung, MC, USA,
LTC Dirk M. Elston, MC, USA, and MAJ Richard A. Keller, MC, USA
Fort Sam Houston, Texas
- Metastatic Crohn's disease of the face** 986
Wenchieh Chen, MD, Ulrike Blume-Peytavi, MD, Sergij Goerdts, MD, and
Constantin E. Orfanos, MD *Berlin, Germany*
- Paraneoplastic urticaria in a patient with ovarian carcinoma** 988
Uwe Reinhold, MD, Thomas Bruske, MD, and Gunnar Schupp, MD
Bonn, Germany
- Intestinal involvement in Sweet's syndrome** 989
Olivier Fain, MD, Emmanuel Mathieu, MD, Nathalie Feton, MD,
Mathilde Sibony, MD, Muriel Sitbon, MD, Françoise Lejeune, MD, and
Michel Thomas, PhD *Bondy, France*
- Cyclosporine in scleredema** 990
Georgia Mattheou-Vakali, MD, Demetris Ioannides, MD,
Thomas Thomas, MD, E. Lazaridou, MD, P. Tsogas, MD, and A. Minas, MD
Thessaloniki, Greece

Continued on page 11A

Persistent cutaneous hypersensitivity reaction after a Hawaiian box jellyfish sting (<i>Carybdea alata</i>)	991
Reid H. Tamanaha, and Allan K. Izumi, MD <i>Honolulu, Hawaii</i>	
Carcinoma erysipelatoides resulting from genitourinary cancer	993
LTC Dirk M. Elston, MC, USA, Ralph J. Tuthill, MD, Joseph Pierson, MD, J. Daniel Marden, MD, and Wilma F. Bergfeld, MD <i>Cleveland, Ohio</i>	
Sweet's syndrome secondary to granulocyte colony-stimulating factor	995
Paula Lyn Prevost-Blank, MD, and Tor Adam Shwayder, MD <i>Detroit, Michigan</i>	
Metastatic cutaneous carcinoid	997
Gary A. McCracken, MD, Carl V. Washington, MD, and Stephen F. Templeton, MD <i>Atlanta, Georgia</i>	
Hereditary anetoderma	999
Angela Peterman, MD, Monica Scheel, MD, W. Mitchell Sams, Jr., MD, and Amit G. Pandya, MD <i>Dallas, Texas, and Birmingham, Alabama</i>	
Superficial cutaneous <i>Nocardia asteroides</i> in an immunocompetent pregnant woman	1000
Georgia A. Kannon, MD, Melanie K. Kuechle, MD, and Algin B. Garrett, MD <i>Richmond, Virginia</i>	
Psoriasis and blue sclerae in girls with Turner syndrome	1002
Catherine Dacou-Voutetakis, MD, and Talia Kakourou, MD <i>Athens, Greece</i>	

CURRENT ISSUES

Primary care in dermatology: Whose role should it be?	1005
David L. Ramsay, MD, MEd, and Peyton E. Weary, MD <i>New York, New York, and Charlottesville, Virginia</i>	
The dermatologist's role in primary care: A primary care physician's view	1009
Barry L. Hainer, MD <i>Charleston, South Carolina</i>	

EDITORIALS

Lifetime risk for development of skin cancer in the U.S. population: Current estimate is now 1 in 5	1012
Darrell S. Rigel, MD, Robert J. Friedman, MD, and Alfred W. Kopf, MD <i>New York, New York</i>	
Surgical margins for malignant melanoma: Another point of view	1014
Matthew H. Kanzler, MD, and Susan M. Swetter, MD <i>Stanford, California</i>	

Continued on page 13A

CORRESPONDENCE

Lentigo maligna and lentigo maligna melanoma	1016
John H. Altshuler, MD <i>Englewood, Colorado</i>	
Reply	1016
Lisa M. Cohen, MD <i>Boston, Massachusetts</i>	
Benign melanocytic lesions	1017
Robin Marks <i>Victoria, Australia</i>	
Reply	1018
Peter J. Heenan and Theresa M. Skender-Kalnenas <i>Nedlands, Western Australia</i>	
Benign melanocytic lesions	1018
S. Elizabeth Whitmore, MD <i>Baltimore, Maryland</i>	
Reply	1019
Peter J. Heenan and Theresa M. Skender-Kalnenas <i>Nedlands, Western Australia</i>	
Cyclosporine and angiogenesis in psoriasis	1019
Vincent W. Li, MD, and William W. Li, MD <i>Cambridge, Massachusetts</i>	
Reply	1020
E. P. Prens, MD, PhD, and R. Debets, PhD <i>Rotterdam, The Netherlands</i>	
Cutaneous reactions to recombinant cytokine therapy	1021
Manuela Papini, MD, and Pier Luigi Bruni, MD <i>Terni, Italy</i>	
Reply	1021
Anthony A. Gaspari, MD <i>Rochester, New York</i>	
Understanding and evaluating clinical trials	1022
Bruce G. Howard, MD <i>Santa Maria, California</i>	

READER SERVICES

Index

Author index	1025
Subject index	1037
Information for authors	23A, 24A, and 25A
Information for readers	26A
Dermatology calendar	77A

Continued on page 14A

Dermatology opportunities	82A
Instructions for Category I CME Credit	28A
CME examination answer sheet	35A
CME examination for volume 36	30A
CME examination answer sheet for volume 36	43A
Answers to CME examination for volume 36	37A
Index to advertisers	74A

Complimentary subscriptions to the Journal of the American Academy of Dermatology are available to dermatology residents, fellows, and osteopathic trainees in the United States and Canada as an educational service by Westwood Squibb Pharmaceuticals, a division of Bristol-Myers Squibb Company.

Treatment of *Candida* nail infection with terbinafine

Rina Segal, MD,^a Aharon Kritzman, MD,^a Lia Cividalli, PhD,^b Zmira Samra, PhD,^b and Michael David, MD^a *Petah Tiqva, Israel*

Background: Terbinafine is a highly potent drug against dermatophytes. Data regarding its effectiveness against *Candida* species are few and variable.

Objective: Our purpose was to evaluate the efficacy and safety of oral terbinafine in patients with *Candida* nail infection.

Methods: In an open-label uncontrolled study, 20 patients completed 16 weeks of treatment with terbinafine, 250 mg/day, and an additional 8 weeks with placebo. Efficacy was assessed clinically and mycologically at weeks 0 (baseline), 4, 8, 16, 24, 36, and 48. Routine laboratory studies were performed at baseline and weeks 4, 8, and 16.

Results: At the end of the trial 60% of target nails were cured clinically and mycologically; in 10% there was mycologic cure with residual clinical signs, in 25% a moderate improvement (>50%), and failure in only 5% (one patient). Most nails were infected by *Candida parapsilosis*. Two of 28 patients showed mild reversible elevation of liver enzymes 1 month after initiation of terbinafine treatment.

Conclusion: The administration of terbinafine for 16 weeks is effective in the treatment of *Candida* nail infection. Liver enzyme values should be determined during the first month of treatment.

(J Am Acad Dermatol 1996;35:958-61.)

The role of *Candida* species as a cause of nail disease has been well established.¹ They cause 1% to 32% of toenail infections and 51% to 70% of fingernail infections, either as the sole pathogen or in combination with dermatophytes or molds.²⁻⁴

Candida albicans accounts for 50%³ to 83%⁴ of *Candida* species causing nail infections, although *C. parapsilosis* is emerging now as the main pathogen in various centers.*

Terbinafine is the first orally active antifungal drug of the allylamines class.⁵ The in vitro minimal inhibitory concentration values of terbinafine against dermatophytes are extremely low (0.001 to 0.01 µg/ml), but the in vitro activity against *Candida* is more variable and species dependent, ranging from 0.1 to 12.5 µg/ml and even higher.^{6,7} It is fungistatic

against *C. albicans* and fungicidal against *C. parapsilosis*.

Numerous studies have confirmed the beneficial effect of the drug against dermatophytes.⁵ However, there have been only a few reports on its efficacy against *Candida* nail infection. It was the purpose of this study to evaluate the efficacy and safety of oral terbinafine in patients with a nail infection caused by *Candida* species.

PATIENTS AND METHODS

This study was carried out as an open-labeled uncontrolled study. The subjects had to have mycologically proven candidal onychomycosis, with or without paronychia disease, to be older than 18 years of age, and to have the values of hematologic tests and blood chemistry within the normal range. All gave informed consent. Excluded from the trial were pregnant or lactating women, patients with a history of peptic ulcer, renal or hepatic dysfunction, immunosuppressed patients with psoriasis or other dermatoses, and patients who had received systemic antifungal therapy during the preceding 6 weeks.

The study was divided into two phases. In phase A, terbinafine, 250 mg/day, was given for 16 weeks. In phase B, a placebo was given for an additional 8 weeks, followed by an off-treatment period of 24 weeks. Patients were assessed mycologically every 4 weeks for the first 24 weeks and every 12 weeks in the remaining 24 weeks.

From the Departments of Dermatology^a and Microbiology,^b Beilinson Medical Centre, Petah Tikva, and the Sackler Faculty of Medicine, Tel-Aviv University.

Supported by a grant from Sandoz Pharma Ltd, Basel, Switzerland.

Reprint requests: Rina Segal, Department of Dermatology, Beilinson Medical Center, Petah Tikva, 49100, Israel.

*Abramson C, Berlin S. Increased incidence of nondermatophyte filamentous fungi in skin and toenail infections. Abstracts of the International Summit on Cutaneous Antifungal Therapy, Boston, 1994.

Copyright © 1996 by the American Academy of Dermatology, Inc. 0190-9622/96 \$5.00 + 0 16/1/74900

Table I. Response to treatment with terbinafine in *Candida* onychomycosis

	Week 16						Week 24						Week 48					
	Target nail		Finger-nails		Toe-nails		Target nail		Finger-nails		Toe-nails		Target nail		Finger-nails		Toe-nails	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Complete cure	2	10	3	15.5	0	0	6	30	4	21	0	0	12	60	12	64	7	36
Mycologic cure or marked improvement (>90%)	1	5	4	21	0	0	3	15	6	31	1	5	2	10	1	5	2	11
Moderate improvement (>50%-<90%)	6	30	3	15.5	4	21	7	35	2	10	10	53	5	25	3	15.5	7	37
Failure (<50%)	11	55	9	48	5	79	4	20	7	38	8	42	1	5	3	15.5	3	16

Target nail = 17 fingernails, 3 toenails; fingernails = (other than target nails), in 19 patients; toenails = (other than target nails) in 19 patients.

Method of assessment

Before treatment, the location of each nail infection was identified and a target nail was selected for mycologic testing and clinical evaluation. All the other infected nails were also assessed clinically at each visit. At each visit, the percentage of nail involvement was recorded and the severity of hyperkeratosis, color changes, and paronychia inflammation were graded on a 0 to 3 scale (0 = none; 1 = mild; 2 = moderate; 3 = severe) for each nail. The mycologic examination of the target nail included potassium hydroxide (KOH) wet mount, culture on Sabouraud media with chloramphenicol, with and without actidione, and identification of candidal species. The clinical response was evaluated statistically with the following scale:

- 1 = Complete cure: No residual clinical signs and negative results of mycologic examination
- 2a = Mycologic cure for target nail, with mild residual clinical signs but negative culture and microscopic findings
- 2b = Marked improvement for all nails other than the target nail, with more than 90% clinical improvement
- 3 = Moderate improvement: Clinical signs and symptoms decreased by more than 50% and less than 90%
- 4 = Failure: Clinical improvement of less than 50%

Statistical analysis

The average improvement per week of the target nail, fingernails, and toenails was calculated. The results were analyzed with the two-sample *t* test for difference in means. The *t* test retains the null hypothesis at the 0.05 level of significance.

RESULTS

Of the 28 patients who entered the study, eight did not complete it: two (7%) because of a reversible liver enzyme elevation after 1 month of medication, two because of dizziness and nausea, and four

because of lack of compliance. Of the 20 patients who completed the 48 weeks of the study, 13 were women and 7 were men (age range, 21 to 68 years [mean, 49.9 years]). In these subjects, the side effects were gastric fullness (two) and dizziness (one).

Table I presents the response to treatment of the target nail and all other fingernails (in 19 patients) and toenails (in 19 patients; five also grew *Trichophyton rubrum*). At the end of the study, 12 target nails (60%) were cured, in two (10%) there was a mycologic cure, in 5 there was moderate improvement, and treatment failed in 1. Of the three target toenails, one was cured and two showed moderate improvement (>80%). A similar response was observed in the infected fingernails (Table I). The response of the toenails was less favorable and improvement was observed only after a longer time, with a complete cure or marked improvement (>90%) in only 49%. Overall, of a total of 75 affected fingernails, 58 (77%) were cured; 85 (67.5%) of the 126 infected toenails were cured.

In 18 of the 20 target nails it was possible to identify the candidal species (Table II). Only three patients were infected with *C. albicans* and in two of them *C. parapsilosis* was also isolated. *C. parapsilosis* was found in 16 of 18 nails: six of them alone and in the rest, in combination with *C. albicans* (two), *C. tropicalis* (four), or *C. lusitana*, *C. fumata*, or *C. rugosa* (four). *C. tropicalis* alone was identified in only one patient. *C. parapsilosis* and *C. tropicalis* infection was manifested mainly as primary distal and lateral onychodystrophy. Total nail involvement was observed in five patients; three of them had paronychia involvement.

Mycologic cure (negative potassium hydroxide and culture) was obtained in 18 patients after a mean

Table II. Distribution of *Candida* species, type of clinical infection, and response to treatment

<i>Candida</i> sp.	No.	%	Type of clinical infection			Time of mycologic cure (wk)	Response to treatment (week 48) (scale of response)*			
			Proximal nail onychia	Distal nail onychia	Total nail involvement		1	2a	3	4
<i>C. albicans</i>	1	5.5	—	—	1†	36	1	—	—	—
<i>C. parapsilosis</i>	6	34	—	5	1	21.3	4	—	2	—
<i>C. tropicalis</i>	1	5.5	—	1	—	24	1	—	—	—
<i>C. albicans</i> , and <i>C. parapsilosis</i>	2	11	2	—	—	38	1	1	—	—
<i>C. parapsilosis</i> and <i>C. tropicalis</i>	3	17	—	2	1†	22.6‡	2	—	1	—
<i>C. parapsilosis</i> and <i>C. lypolytica</i> , <i>C. fumata</i> , or <i>C. rugosa</i>	5	27.5	—	3	2†	30.6‡	1	1	2	1

*Scale of response: 1 = Cure; 2a = mycologic cure; 3 = moderate improvement; 4 = failure.

†Total nail involvement with paronychia.

‡Two patients did not achieve mycologic cure.

time of 25.8 ± 2.3 weeks (range, 4 to 40 weeks) (Table II). The mycologic cure time for *C. albicans* was 37.7 weeks and for *C. parapsilosis* and *C. tropicalis* was an average of 22 to 24 weeks. The combination of *C. lypolytica*, *C. fumata*, or *C. rugosa* lengthened the time for mycologic cure to an average of 30.6 weeks. The most rapid response was in infections caused by *C. parapsilosis*, whereas the response by *C. albicans* was obvious only after 24 weeks of treatment.

During the follow-up period of 8 months only one patient had a relapse and this occurred at approximately 48 weeks.

DISCUSSION

Therapy with oral terbinafine for 3 months produces a cure rate of more than 80% in dermatophytosis of the nails.⁸ For candidial nail infections, however, differing results have been reported.^{9,10}

Our results showed that fingernail infections responded better to terbinafine than toenail infections. The continuing clinical and mycologic improvement after cessation of treatment and the relatively low relapse rate imply that terbinafine continues to be active in the nailplate for more than 6 months. However, no studies have been done of the presence of terbinafine in the nailplate more than 90 days after its discontinuation.^{11,12}

Onychomycosis caused by *Candida* species is relatively frequent in Israel. In our study group, *C.*

parapsilosis was more common than *C. albicans* as the pathogen. Most patients had distal nail dystrophy; none of them had peripheral vascular disease.

Evaluation after 16 weeks of treatment showed an earlier and better response to treatment by *C. parapsilosis* than by *C. albicans*, but after 48 weeks the end results were almost identical. This pattern of response can be explained by the fact that terbinafine is fungicidal for *C. parapsilosis* and fungistatic for *C. albicans*. Nails infected with rather rare species of *Candida* (*C. lypolytica*, *C. fumata*, *C. rugosa*) showed mild or moderate improvement. Unfortunately, we were unable to determine the minimal inhibitory concentration values for the various species of *Candida*.

Only two previous studies have evaluated the efficacy of terbinafine for *Candida* nail infection. The first by Roberts et al.⁹ gave terbinafine for 12 weeks or up to 24 weeks in nonresponders. The improvement after 12 weeks was not significant, and follow-up results were not conclusive. Nolting, Brautigam, and Weidinger¹⁰ treated their patients for 48 weeks. Clinical and mycologic cures were achieved in 52% of toenails and in 65% of fingernails. The cure rates according to pathogen were 63% for *C. parapsilosis* and 54% for *C. albicans*. Our results are in accord with these.

Overall, in our study terbinafine was well tolerated. The only relevant adverse reaction was a reversible elevation of liver enzymes in 2 (7%) of 28 patients.

REFERENCES

1. Hay RJ, Baran R, Moore MH, et al. *Candida* onychomycosis: an evaluation of the role of *Candida* species in nail disease. *Br J Dermatol* 1988;118:47-58.
2. Willemssen M. Changing patterns in superficial infections: focus on onychomycosis. *J Eur Acad Dermatol Venereol* 1993;2(suppl):S6-S11.
3. Clayton YM. Clinical and mycological diagnostic aspects of onychomycosis and dermatomycoses. *Clin Exp Dermatol* 1992;17(suppl 1):37-40.
4. Budak A, Macura AB, Mazur T, et al. Fungal species isolated from skin and nail of hands and feet of patients suspected of mycotic infection. *Mykosen* 1987;30:434-9.
5. Balfour JA, Faulds D. Terbinafine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. *Drugs* 1992;43:258-84.
6. Shadomy S, Espinel I, Groff A, et al. In vitro studies with SF 86-327: a new orally active allylamine derivative. *Sa-bouraud* 1985;23:125-32.
7. Clayton YM. In vitro activity of terbinafine. *Clin Exp Dermatol* 1989;14:101-3.
8. Goodfield MJD. Short duration therapy with terbinafine for dermatophyte onychomycosis: a multicenter trial. *Br J Dermatol* 1992;126 (suppl 29):33-5.
9. Roberts DT, Richardson MD, Dwyer PK, et al. Terbinafine in chronic paronychia and *Candida* onychomycosis. *J Dermatol Treat* 1992;3(suppl 1):38-42.
10. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by nondermatophytic fungi. *Br J Dermatol* 1994;130(suppl 43):16-21.
11. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, str. corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally and daily for 7 and 14 days. *Clin Exp Dermatol* 1994;19:121-6.
12. Finlay AY. Pharmacokinetics of terbinafine in the nail. *Br J Dermatol* 1992;126(suppl 39):28-32.